Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
-	Nivolumab	Opdivo®	Is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma. Rapid Review	Assessment Process Complete	18th March 2016
22046	Nivolumab	Opdivo®	Is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC.	NCPE Assessment Process Complete	21st February 2024
-	Nivolumab	Opdivo®	Is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.	Assessment Process Complete	12th October 2016
-	Nivolumab	Opdivo®	Opdivo® is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.	Assessment Process Complete	10th March 2016
22045	Nivolumab	Opdivo®	Nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell PD-L1 (programmed death ligand 1) expression ≥1%.	Rapid Review Complete	20th October 2023
-	Nivolumab	Opdivo®	As monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.	Assessment Process Complete	12th September 2018
-	Nivolumab	Opdivo®	Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC) for RCC.	Assessment Process Complete	8th January 2020
21023	Nivolumab	Opdivo®	Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.	NCPE Assessment Process Complete	6th July 2023
23050	Nivolumab	Opdivo®	In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%.	Rapid Review Complete	5th June 2024
21018	Nivolumab in combination with ipilimumab	Opdivo® plus Yervoy®	Nivolumab in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.	NCPE Assessment Process Complete	7th September 2022
-	Nivolumab plus ipilimumab	Opdivo® plus Yervoy®	For the treatment of advanced melanoma.	Rapid Review Complete	9th November 2016
21014	Nivolumab plus ipilimumab plus platinum-doublet chemotherapy	Opdivo® plus Yervoy®	For the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumours have no sensitising EGFR mutation or ALK translocation.	Rapid Review Complete	30th April 2021
24009	Nivolumab+relatlimab	Opdualag®	Nivolumab+relatlimab (Opdualag® ) is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.	Rapid Review Complete	16th April 2024
-	Nomegestrol acetate/estradiol	Zoely®	Nomegestrol acetate/estradiol (Zoely®) oral contraception	Rapid Review Complete	3rd January 2012
20044	Nusinersen	Spinraza®	For the treatment of 5q spinal muscular atrophy (SMA) in adults patients (>18 years).	Rapid Review Complete	29th October 2020
-	Nusinersen	Spinraza®	Is indicated for the treatment of 5q spinal muscular atrophy (SMA)	Assessment Process Complete	19th December 2017
-	Obeticholic acid	Ocaliva®	For the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.	Assessment process complete	31st October 2017
-	Obinutuzumab	Gazyvaro®	In combination with bendamustine followed by obinutuzumab maintenance for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.	Assessment process complete	26th January 2017
-	Obinutuzumab	Gazyvaro®	In combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.	Assessment process complete	2nd April 2015
-	Obinutuzumab	Gazyvaro®	In combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.	Assessment process complete	3rd May 2018
-	Ocrelizumab	Ocrevus®	For the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.	Assessment process complete	4th October 2018
-	Ocrelizumab	Ocrevus®	For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Assessment process complete	29th August 2018
-	Ocriplasmin	Jetrea®	For the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.	Rapid Review Complete	11th July 2013
21058	Odevixibat	Bylvay®	For the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.	NCPE Assessment Process Complete	14th March 2023
-	Ofatumumab	Arzerra®	In combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.	Rapid Review Complete	18th December 2014
-	Ofatumumab	Arzerra®	For the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.	Rapid Review Complete	22nd June 2010
21008	Ofatumumab	Kesimpta®	For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Assessment process complete	16th April 2021
-	Oladaterol	Striverdi®, Respimat®	As a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).	Rapid Review Complete	6th May 2014
-	Olaparib	Lynparza®	For the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.	Assessment process complete	30th March 2020
22065	Olaparib	Lynparza®	As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.	NCPE Assessment Process Complete	24th September 2024
-	Olaparib	Lynparza®	As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.	Assessment process complete	17th December 2015
-	Olaparib	Lynparza®	For the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments.	Rapid Review Complete	10th April 2019
21019	Olaparib	Lynparza®	As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.	Rapid Review Complete	15th June 2021
-	Olaparib	Lynparza®	As monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.	Assessment process complete	2nd February 2020
23029	Olaparib	Lynparza®	Olaparib in combination with abiraterone and prednisone or prednisolone is indicated for the treatment of adult patients with mCRPC in whom chemotherapy in not clinically indicated	NCPE assessment ongoing	19th December 2024
21011	Olaparib	Lynparza®	Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.	NCPE Assessment Process Complete	20th October 2023
-	Olaparib	Lynparza®	As monotherapy for the maintenance treatment of adult patients with BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. This is a sub-group of the entire licensed population.	Rapid Review Complete	6th August 2019
24029	Olaparib	Lynparza®	Olaparib (Lynparza®) is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen	Rapid Review Complete	13th August 2024
23014	Olipudase alfa	Xenpozyme®	As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.	Rapid Review Complete	31st March 2023
-	Omalizumab	Xolair®	As an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.	Rapid Review Complete	25th June 2014
-	Omalizumab	Xolair®	As an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.	Assessment process complete	25th June 2015
24033	Omaveloxolone	Skyclarys®	For the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older	Pre submission consultation scheduled	4th December 2024
-	Omega-3-acid ethyl esters	Omacor®	As an adjuvant treatment in secondary prevention after myocardial infarction in addition to other standard therapy.  Omacor® is also indicated for the treatment of endogenous hypertriglyceridaemia as a supplement to diet, when dietary measures alone are insufficient to produce an adequate response.	Assessment process complete	22nd April 2013
20049	Omeprazole 2mg/ml powder for oral suspension	Pedippi®	For the management of  Gastro-oesphageal reflux disease (GORD) and Peptic Ulcer Disease (PUD) in children and adult patients. Please refer to the SPC for the full range of licensed indications. The Applicant is seeking reimbursement for a subgroup of the licensed population: Children over 1 month of age for the treatment of  reflux esophagitis and symptomatic treatment of heartburn and acid regurgitation in gastro oesophageal reflux disease (GORD); Children over 4 years of age and adolescents in combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori (H. pylori).	Rapid Review Complete	11th February 2021
20021	Onasemnogene abeparvovec	Zolgensma®	For the treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.	Assessment process complete	2nd April 2021
20055	Opicapone	Ongentys®	As adjunctive therapy to levodopa and DOPA decarboxylase inhibitors (L-DOPA+DDCI) in adults with Parkinson’s disease and end-of-dose motor fluctuations in patients not stabilised on such combinations.	Rapid Review Complete	18th January 2021
-	Opium Tincture	Dropizol®	For severe diarrhoea such as diarrhoea caused by cytostatic medication, radiation or neuroendocrine tumours when use of other anti-diarrhoea treatments have not given sufficient effect.	Rapid Review Complete	3rd April 2019
22070	Oral Azacitidine	Onureg®	For maintenance treatment in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation.	Rapid Review Complete	14th March 2024
21061	Oritavancin	Tenkasi®	For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Rapid Review Complete	24th January 2022
22023	Osilodrostat	Isturisa®	For the treatment of endogenous Cushing’s syndrome in adults.	Rapid Review Complete	17th May 2022